Jorge Castellanos, MD
Interventional Cardiology · Baton Rouge, LANPI 1376792879
Payments from drug & device makers
Across 672 payments — averaging $834.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Edwards Lifesciences$471K
- Abbott$73K
- Medtronic$9K
- Boston Scientific$3K
- Ancora Heart, Inc.$3K
- Philips North America LLC$873
- plus $2K from 26 others
What the payments were for
- Consulting fees$125,72568%
- Speaking & faculty fees$4,5002%
- Travel & lodging$30,11316%
- Food & beverage$24,90613%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Edwards Lifesciences | 373 | $471,103 |
| Abbott | 155 | $72,577 |
| Medtronic(2 entities) | 42 | $8,721 |
| Boston Scientific | 34 | $3,163 |
| Ancora Heart, Inc. | 9 | $2,740 |
| Philips North America LLC | 4 | $873 |
| Abiomed | 6 | $401 |
| Angiodynamics, Inc. | 2 | $287 |
| Siemens Medical Solutions USA, Inc. | 3 | $205 |
| Shockwave Medical, Inc | 1 | $109 |
| E.r. Squibb & Sons, L.L.C. | 5 | $73 |
| Pfizer | 5 | $73 |
| Boehringer Ingelheim | 3 | $50 |
| Kestra Medical Technology Services, Inc. | 2 | $49 |
| Novartis | 3 | $47 |
| Amgen | 3 | $44 |
| Johnson & Johnson | 3 | $40 |
| AstraZeneca | 2 | $35 |
| Esperion Therapeutics, Inc. | 2 | $32 |
| Akcea Therapeutics, Inc. | 1 | $29 |
| Cleerly, Inc. | 1 | $27 |
| Chiesi USA, Inc. | 2 | $27 |
| Arbor Pharmaceuticals, Inc. | 2 | $26 |
| Cardiva Medical, Inc. | 1 | $26 |
| Sanofi-aventis U.S. LLC | 1 | $24 |
| Baxter Healthcare | 1 | $24 |
| Alnylam Pharmaceuticals Inc. | 1 | $24 |
| Bardy Diagnostics, Inc. | 1 | $21 |
| Heartflow, Inc. | 1 | $21 |
| Amarin Pharma, Inc. | 1 | $18 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $17 |
| Kowa Pharmaceuticals America, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Edwards SAPIEN 3 Transcatheter Heart Valve$97,867
- PASCAL$47,052
- MitraClip$2,945
- Edwards SAPIEN 3 Ultra Transcatheter Heart Valve$2,842
- AccuCinch$2,641
- COREVALVE EVOLUT R$2,447
- EVOQUE$2,160
- SAPIEN 3 Ultra RESILIA$1,675
- Mitra Clip system$1,075
- Watchman$841
- (9148) ICE 3D$839
- MitraClip System$518
- AMPLATZER$392
- AMPLATZER AMULET$355
- Impella$288
- AngioVac$194
- General - Balloon Catheters$142
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$109
- Reveal LINQ$101
How this compares
$560,915 in reported general payments places this provider in the 90th percentile of 171 interventional cardiology providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 82 | $67,776 |
| JardianceEmpagliflozin | 33 | $30,764 |
| XareltoRivaroxaban | 19 | $30,223 |
| EntrestoSacubitril/Valsartan | 36 | $27,829 |
| ClopidogrelClopidogrel Bisulfate | 91 | $1,232 |
| Atorvastatin Calcium | 71 | $1,124 |
| Metoprolol Succinate | 68 | $703 |
| Chlorthalidone | 11 | $324 |
| Lisinopril-HydrochlorothiazideLisinopril/Hydrochlorothiazide | 12 | $254 |
| Carvedilol | 19 | $227 |
| Amlodipine Besylate | 29 | $182 |
| Rosuvastatin Calcium | 18 | $181 |
| Losartan Potassium | 15 | $160 |
| Spironolactone | 19 | $132 |
| Furosemide | 21 | $82 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $73 | $67,77682 claims |
| Boehringer IngelheimJardiance | $50 | $30,76433 claims |
| Johnson & JohnsonXarelto | $40 | $30,22319 claims |
| NovartisEntresto | $47 | $27,82936 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 171 interventional cardiology providers in Louisiana.
Other interventional cardiology in Baton Rouge
- Denzil MoraesBaton Rouge$1.4M
- Venkata GadiBaton Rouge$132K
- Steven KelleyBaton Rouge$116K
- Andrew ReesBaton Rouge$95K
- Garland GreenBaton Rouge$37K
- Harold HelmkeBaton Rouge$32K
- Lance LamotteBaton Rouge$24K
- Craig WalkerHouma$5.5M
- Naseem JaffraniAlexandria$5.1M
- Mark NapoliMonroe$2.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.